中文摘要：

目的：探讨肾移植后高血压患者中CYP3A4^＊1G、CYP3A5^＊3基因多态性对他克莫司血药浓度/剂量比（C/D）的影响。方法：以70例肾移植后高血压患者为研究对象,使用PCRRFLP法和测序法检测患者CYP3A4^＊1G、CYP3A5^＊3基因型,患者连续服用他克莫司至少达3 d后,采用微粒子酶免疫分析法（MEIA）测定患者的他克莫司血药谷浓度（C0）,比较CYP3A4^＊1G和CYP3A5^＊3基因多态性对患者他克莫司血药浓度/剂量比（C/D）的影响。结果：肾移植后高血压患者中,携带CYP3A4^＊1G野生型（^＊1^＊1）患者的他克莫司C/D明显高于CYP3A4突变杂合子（^＊1^＊1G）和CYP3A4突变纯合子（^＊1G^＊1G）携带者（P〈0.05）;CYP3A5^＊3突变纯合子（^＊3^＊3）患者的他克莫司C/D明显高于CYP3A5野生型（^＊1^＊1）和CYP3A5突变杂合子（^＊1^＊3）基因型患者（P〈0.05）。要达到相同的目标血药浓度,CYP3A4^＊1G的^＊1^＊1G和^＊1G^＊1G患者比^＊1^＊1患者需要更高剂量的他克莫司,CYP3A5^＊3的^＊1^＊1和^＊1^＊3患者比^＊3^＊3患者需要更高剂量的他克莫司。结论：CYP3A4^＊1G、CYP3A5^＊3基因多态性与肾移植后高血压患者的他克莫司C/D显著相关。

英文摘要：

AIM： To study the effects of CYP3A4^＊1G and CYP3A5^＊3 gene polymorphism on concentration / dose ratio（ C / D） of tacrolimus.METHODS： Seventy patients with post renal transplant hypertension were screened in the study. Polymerase restrictive fragment length polymorphism（ PCR-RFLP） and PCR sequencing PCR technique were used to detect the CYP3A4^＊1G and CYP3A5^＊3 gene polymorphism. Tacrolimus trough level（ C0）was determined by microparticle enzyme immunoassay（ MEIA） when tacrolimus was administrated at a stable dose for at least 3 days. RESULTS： Among the patients with post renal transplant hypertension,C / D of tacrolimus for patients with CYP3A4^＊1^＊1was higher than that of those with CYP3A4-＊1-＊1G and CYP3A4^＊1G^＊1G（ P〈0. 05）. C / D of tacrolimus for patients with CYP3A5^＊3-＊3 was higher than that of those CYP3A5^＊1^＊1 and CYP3A5^＊1^＊3（ P〈0. 05）. CYP3A4^＊1^＊1G and CYP3A4^＊1G-＊1G patients required higher dosage of tacrolimus than CYP3A4^＊1^＊1 patients,and CYP3A5^＊1^＊1 and CYP3A5-＊1-＊3 patients required higher dosage of tacrolimus than the CYP3A5^＊3^＊3 patients to get similar plasma tacrolimus concentration. CONCLUSION： C / D of tacrolimus is significantly associated with the CYP3A4^＊1G and CYP3A5^＊3 gene polymorphism.